glp 1 microdosing side effects GLP-1 Microdosing GLP-1s: Reduce Inflammation, Support

Food and Drug Administration (FDA) specifically for weight management : Saxenda (liraglutide) Novo Nordisk Wegovy (semaglutide) Novo Nordisk Zepbound (tirzepatide) Eli Lilly Although Saxenda received approval in 2014, it was not until Wegovys launch in 2021 that the weight loss potential of GLP-1s gained widespread public attention

* These statements have not been evaluated by the Food and Drug Administration

This normally enhances insulin release from the beta cells while suppressing glucagon release from the alpha cells, which also lie in the pancreas

It is also approved for use in children aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m 2 for adults (obese)

While its Q1 revenue contribution will be minimal, managements commentary on early prescription trends, pricing, patient uptake, and 2026 outlook will be the highlight of the call